Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Milnacipran for fibromyalgia.

J Dempsey

    Issues in Emerging Health Technologies
    |March 22, 2008
    PubMed
    Summary
    This summary is machine-generated.

    Milnacipran shows potential for treating fibromyalgia, a chronic pain condition. However, further research is needed to confirm its safety, efficacy, and optimal use in patient care.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Gastric heterotopia in a gall bladder.

    Irish journal of medical science·2016
    Same author

    Genetic and treatment-related risk factors associated with external apical root resorption (EARR) concurrent with orthodontia.

    Orthodontics & craniofacial research·2015
    Same author

    Visual sex discrimination in goldfish: seasonal, sexual, and androgenic influences.

    Hormones and behavior·2004
    Same author

    Immunological and hematological effects observed in B6C3F1 mice exposed to JP-8 jet fuel for 14 days.

    Journal of toxicology and environmental health. Part A·2004
    Same author

    Changes in body mass indices of patients with schizophrenia 3 years following the introduction of a weight management programme.

    Irish medical journal·2004
    Same author

    IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis.

    Regulatory toxicology and pharmacology : RTP·2001
    Same journal

    Laparoscopic diaphragm pacing for tetraplegia.

    Issues in emerging health technologies·2009
    Same journal

    Implantable hemodynamic monitoring (the Chronicle IHM system): remote telemonitoring for patients with heart failure.

    Issues in emerging health technologies·2008
    Same journal

    Rotigotine transdermal patches (Neupro) for the treatment of Parkinson's disease.

    Issues in emerging health technologies·2008
    Same journal

    Continuous erythropoietin receptor activator (Mircera) for renal anemia.

    Issues in emerging health technologies·2008
    Same journal

    Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.

    Issues in emerging health technologies·2007
    Same journal

    Human papillomavirus (HPV) vaccines: a Canadian update.

    Issues in emerging health technologies·2007
    See all related articles

    Area of Science:

    • Pharmacology
    • Pain Management
    • Clinical Trials

    Background:

    • Fibromyalgia is a chronic pain disorder impacting many individuals.
    • Milnacipran, an antidepressant, is being investigated for fibromyalgia treatment.
    • Existing evidence suggests potential benefits but also highlights adverse effects.

    Purpose of the Study:

    • To evaluate the safety and efficacy of milnacipran for fibromyalgia.
    • To determine optimal dosing strategies for milnacipran.
    • To clarify the role of milnacipran in comprehensive fibromyalgia management.

    Main Methods:

    • Phase 3 clinical trials were conducted to assess milnacipran.
    • Data collection focused on efficacy and adverse event profiles.
    • Analysis aimed to identify patient subgroups who may benefit.

    Related Experiment Videos

    Main Results:

    • Preliminary findings indicate potential therapeutic benefits of milnacipran in some fibromyalgia patients.
    • Adverse effects associated with milnacipran may pose limitations to its clinical application.
    • Complete phase 3 trial results are pending publication.

    Conclusions:

    • Milnacipran demonstrates preliminary promise for fibromyalgia symptom management.
    • Further investigation is crucial to establish long-term safety and sustained efficacy.
    • Optimal use and comparative effectiveness require additional research.